Lucira Health, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067
The investigation concerns whether Lucira and certain of its directors and/or officers have engaged in securities fraud or other unlawful business practices. Pre-market, Lucira issued a press release on October 8, 2021 reporting that its supply partner Copan Italia SPA had announced a recall of its FLOQSwabs, which were included in the LUCIRA COVID-19 All-In-One Test Kit, as well as it’s LUCIRA CHECK IT COVID-19 Test Kit. It was stated in this press release that “[a]ccording to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and that the recalled Copan swabs should not be used and instead should be disposed. On October 8, 2021 Lucira’s stock price dropped sharply during intraday trading on this news, damaging investors.